GLP-1 Management for PCOS

At PCOS Sisters, we provide GLP-1 treatment designed specifically for women with PCOS. Our PCOS specialists focus on hormone balance, insulin resistance, and long-term metabolic health.

GLP-1 medications like semaglutide (the active ingredient in Wegovy & Ozempic) can be powerful tools for improving insulin resistance and supporting weight loss in PCOS. While GLP-1’s are becoming popular, success depends on more than just the prescription. It depends on how the medication is titrated, monitored, and individualized by providers who treat PCOS specifically, not just obesity.

Trusted PCOS-Specialized Care

*PCOS Sisters membership required

What Are GLP-1 Medications?

GLP-1 medications are a class of treatments that help regulate blood sugar, improve insulin signaling, and support appetite regulation. These medications work through the insulin pathway, which plays a central role in PCOS.

In 2023, semaglutide (the active ingredient in Wegovy & Ozempic) was added to updated PCOS treatment guidance due to its ability to address insulin resistance; one of the underlying drivers of PCOS symptoms.

By improving insulin function, GLP-1 medications can help:

For many women with PCOS, addressing insulin resistance is one of the most effective ways to improve hormone balance and long-term health.

Why GLP-1 Treatment for PCOS Requires a Specialist

GLP-1 medications are often prescribed in a way that focuses only on obesity. But PCOS is a hormonal condition, not simply a weight problem.

At PCOS Sisters, GLP-1 therapy is managed through a hormone-first approach that considers:

insulin resistance
androgen excess
metabolic health
long-term weight maintenance
nutrient depletion risks
individualized dosing

When GLP-1 medications are managed by providers who specialize in PCOS, treatment can be optimized to:

reduce side effects
maximize metabolic improvement
support sustainable results

Our Approach to GLP-1 Management

Unlike many healthcare companies that offer standard dosing protocols, PCOS Sisters focuses on individualized GLP-1 strategies designed for PCOS patients. Your PCOS Specialist will work directly with you to determine what you need. Our approach can include, but is not limited to:

GLP-1 Microdosing

Some patients respond better to smaller, customized dosing rather than standard protocols. Microdosing allows treatment to be tailored to your body’s response.

Oral GLP-1 Options

For patients who are super responders or uncomfortable with injections, oral GLP-1 options may be available.

Combination Treatment Strategies

GLP-1 medications and metformin can both lower vitamin B12 levels, and B12 deficiency is already more common in PCOS patients. Combination medication options may help support optimal nutrient levels.

Long-Term PCOS Maintenance Plans

One of the biggest challenges after GLP-1 treatment is preventing weight regain. PCOS Sisters focuses on long-term strategies that may include: metabolic support medications, insulin-targeted therapies, & hormone-informed maintenance plans

GLP-1 treatment at PCOS Sisters is often incorporated into our broader evidence backed metabolic program. Many patients participate in the PCOS Sisters Metabolic Weight Loss Program™, which combines GLP-1 medications with lifestyle management and PCOS-specific metabolic support. This integrated approach allows our providers to address insulin resistance, hormone balance, and long-term metabolic health together rather than focusing on weight loss alone. You can view our before and after gallery here.

Disclaimer: Our clinical weight loss program is informed by a retrospective chart review and early program evaluation. Evaluation conducted in collaboration with Emory University School of Nursing. Manuscript submission to peer review journal in progress. Weight loss results will vary from individual to individual and are not guaranteed.

GLP-1 Treatment Options and Ongoing Care

PCOS Sisters offers GLP-1 treatment options designed specifically for women with PCOS and their unique metabolic and hormonal needs.

Treatment plans are individualized and may include:

Semaglutide (the active ingredient in Wegovy & Ozempic) and other GLP-1 medications selected based on your health profile
Oral GLP-1 options for patients who are super responders or prefer to avoid injections
Combination treatment strategies, including medications that support nutrient balance when using GLP-1 or metformin
Long-term PCOS maintenance plans designed to help prevent weight regain after GLP-1 treatment
Ongoing provider monitoring and medication management to ensure treatment remains safe and effective

Your provider will help determine the safest and most effective approach based on your symptoms, metabolic health, and treatment goals.

GLP-1 management is available through the PCOS Sisters Membership program, which provides ongoing access to specialized PCOS care, the PCOS Sisters Fitness app and individualized treatment planning.

$150* per month.

PCOS Sisters Membership required.

PCOS Sisters Metabolic Weight Loss Program™

PCOS Weight Loss Albuquerque, NM

Symptoms

PCOS Treatment Details

Patient lost 80 lbs in one year utilizing tirzepatide and the PCOS Sisters customized fitness program. Irregular cycles and thinning scalp hair have resolved.

For many women, losing weight is already a challenge—but with PCOS, it can feel nearly impossible. Hormonal imbalances, insulin resistance, and metabolic changes all play a role in making weight loss with PCOS uniquely difficult. That’s why The PCOS Sisters Metabolic Weight Loss Program™ helps you achieve your goals through a combination of lifestyle coaching, nutrition and fitness support, and medications such as GLP-1s when appropriate. PCOS Sister Membership includes access to our PCOS Sisters Fitness App made specifically for lifestyle and fitness coaching with PCOS women in mind.

The PCOS Sisters Metabolic Weight Loss Program™ is backed by early program evaluation data in collaboration with Emory University School of Nursing. Our preliminary results were presented at the AE-PCOS Annual Meeting 2025. Visit our Research Page to follow updates and see the published outcomes once available.